Vaximm

Developing oral T-cell immunotherapies

VAXIMM develops immunotherapies for patients suffering from cancer. VAXIMM was formed in 2008 as a joint venture of BB Biotech Ventures and Merck KGaA, Darmstadt, Germany.

In 2022 Vaximm sold its neoantigen assets to NEC, after which it sold its oncology assets to BCM Europe.